BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given an average rating of “Moderate Buy” by the fourteen analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $133.96.

Several research firms recently commented on BNTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. JPMorgan Chase & Co. decreased their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday. Morgan Stanley decreased their target price on BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th.

Institutional Investors Weigh In On BioNTech

A number of hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its stake in BioNTech by 6.7% in the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock valued at $135,800,000 after acquiring an additional 80,005 shares during the period. Bank of New York Mellon Corp grew its stake in BioNTech by 58.8% in the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after acquiring an additional 410,351 shares during the period. Dodge & Cox acquired a new stake in BioNTech in the second quarter valued at approximately $93,421,000. Franklin Resources Inc. grew its stake in BioNTech by 76.8% in the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after acquiring an additional 326,556 shares during the period. Finally, Aberdeen Group plc grew its stake in BioNTech by 87.2% in the second quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after acquiring an additional 336,260 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BNTX opened at $105.66 on Friday. BioNTech has a 1 year low of $81.20 and a 1 year high of $129.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The company has a market capitalization of $25.40 billion, a price-to-earnings ratio of -66.04 and a beta of 1.45. The business has a 50-day moving average of $103.20 and a 200-day moving average of $104.46.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. During the same quarter last year, the business earned ($3.36) earnings per share. BioNTech’s revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that BioNTech will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.